Skip to content

Influence of the Use of Specific Nutritional Formulas on Time in Range in Patients With Type 2 Diabetes

Influence of the Use of Specific Nutritional Formulas for Diabetes on Time in Range in Patients With Type 2 Diabetes Mellitus With Obesity by Freestyle Continuous Glucose Monitoring

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07666581
Enrollment
198
Registered
2026-06-24
Start date
2026-08-01
Completion date
2028-12-01
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity & Overweight, Time in Range, Type 2 Diabetes

Keywords

Type 2 Diabetes, Obesity, Continuos Glucose Monitoring, Time in Range

Brief summary

Who can participate? Individuals may be eligible to join this study if they meet the following criteria: * Are 18 years or older. * Have Type 2 diabetes with an A1c level higher than 7%. * Have a Body Mass Index (BMI) between 27 and 35 (considered overweight or Class 1 obesity). * Have used a continuous glucose monitor (CGM) successfully in the past. How the study works: If eligible individuals decide to join and sign the consent form, a computer will randomly assign them into one of two groups: The Formula Group: Participants will replace their usual breakfast and one snack with a specific diabetes nutritional drink (Glucerna®). The Standard Diet Group: Participants will follow a standard low-calorie meal plan without using the nutritional drink. Both groups will aim for a specific daily calorie goal (1,200-1,500 for women; 1,500-1,800 for men) and will receive expert nutritional counseling. Monitoring and Follow-up Over the course of 3 months, close contact will be maintained to support participants: Every 2 weeks: A nutrition expert will call participants to check on their diet and help with their glucose monitor. Every month: Participants will meet with the study team in person to review glucose monitor data. Tests: At the start and end of the study, weight, body composition, blood sugar (A1c), and cholesterol levels will be measured to see how the plans worked.

Detailed description

A randomized controlled clinical trial will be conducted with two parallel groups, which will include patients over 18 years of age with type 2 DM, HbA1c \> 7%, and grade 1 obesity (BMI \>27 kg/m2 and \<35 kg/m2), who have previously used continuous glucose monitoring (CGM) with adherence greater than 70%, and who are able to follow the study protocol. After signing the informed consent, REDcap® will be used to computer-generate the random sequence for group assignment; the intervention group will use a specific nutritional formula for diabetes (FNED) (Glucerna®) (Appendix 1) as a replacement for breakfast and snack to achieve targets of 1200 to 1500 kcal for women and 1500 to 1800 kcal for men, and the control group will continue to be prescribed a low-calorie diet of 1200 to 1500 kcal for women and 1500 to 1800 kcal for men without the use of FNED for a period of 3 months. Both groups will receive nutritional counseling according to the diabetes support and self-care education plan. CGM, body composition, and baseline paraclinical variables will be collected, and every 14 days, adherence to dietary treatment will be verified by telephone using a 24-hour multi-step reminder with advice from a dietary team, and correct use of the device will be verified. CGM records are reviewed in person monthly using the LibreView" platform. CGM data, body composition and HbA1c, total cholesterol, HDL, LDL, baseline triglycerides will be analyzed at 3 months of follow-up.

Interventions

DIETARY_SUPPLEMENTGlucerna

A calorie-restricted diet plan is prescribed (see Table 1). In this group, Glucerna will be prescribed for breakfast and snacks as part of the total calories calculated for each patient's meal plan. Dietary plan prescription of 1200 to 1500 kcal for women and 1500 to 1800 kcal for men.

OTHERCaloric restriction

Dietary plan prescription of 1200 to 1500 kcal for women and 1500 to 1800 kcal for men.

Sponsors

Hospital Universitario San Ignacio
Lead SponsorOTHER
Abbott Nutrition
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years of age. * Diagnosis of diabetes mellitus type 2. * HbA1c \>7% to \<11%. * BMI \>27 kg/mt2 \<35 kg/mt2 * Current use of continuous glucose monitoring with adherence greater than 70%. * Access to technology to download data from CGM in a timely manner. * Ability to follow the study protocol and provide informed consent (Appendix 3).

Exclusion criteria

* Change in antidiabetic medication in the last 3 months. * Pregnancy or lactation or planning to become pregnant during the study period. * Acute decompensation of diabetes in the past 3 months. * Participation in another clinical trial. * Use of glucocorticoids or insulin in the past 3 months or planned use in the coming months. * Initiation of treatment with oral or injectable GLP-1 analogues 3 months prior to enrollment. * History of bariatric surgery or gastrointestinal pathology associated with malabsorption syndromes.

Design outcomes

Primary

MeasureTime frameDescription
Time in range3 monthsTime in range 70 - 180 mg/dl

Secondary

MeasureTime frameDescription
HbA1c3 monthsHbA1c
Weight3 monthsWeight in kilograms
body composition3 monthsfat mass, musculoskeletal mass, visceral fat mass

Countries

Colombia

Contacts

CONTACTAna M Gómez - Medina, Endocrinologyst
agomez@husi.org.co+57 601 5946161
CONTACTDiana C Henao-Carrillo, Endocrinologyst
dchenao@husi.org.co+57 601 5946161
PRINCIPAL_INVESTIGATORAna M Gómez-Medina, Endocrinologyst

Hospital Universitario San Ignacio

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026